New York State Teachers Retirement System increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 5.9% during the first quarter, HoldingsChannel reports. The firm owned 107,084 shares of the company’s stock after buying an additional 5,931 shares during the period. New York State Teachers Retirement System’s holdings in Omnicell were worth $8,657,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in OMCL. Teton Advisors Inc. boosted its stake in Omnicell by 1.6% in the fourth quarter. Teton Advisors Inc. now owns 63,677 shares of the company’s stock valued at $3,900,000 after acquiring an additional 1,000 shares in the last quarter. Comerica Bank boosted its stake in Omnicell by 1.2% in the fourth quarter. Comerica Bank now owns 74,551 shares of the company’s stock valued at $4,685,000 after acquiring an additional 866 shares in the last quarter. Redmond Asset Management LLC boosted its stake in Omnicell by 2.3% in the first quarter. Redmond Asset Management LLC now owns 15,971 shares of the company’s stock valued at $1,291,000 after acquiring an additional 355 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Omnicell by 17.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,594 shares of the company’s stock valued at $159,000 after acquiring an additional 376 shares in the last quarter. Finally, Segall Bryant & Hamill LLC boosted its stake in Omnicell by 30.4% in the fourth quarter. Segall Bryant & Hamill LLC now owns 61,898 shares of the company’s stock valued at $3,791,000 after acquiring an additional 14,446 shares in the last quarter. Hedge funds and other institutional investors own 95.63% of the company’s stock.

Several brokerages have weighed in on OMCL. BidaskClub upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a research note on Saturday, May 4th. Zacks Investment Research downgraded shares of Omnicell from a “hold” rating to a “sell” rating in a research note on Monday, March 25th. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $79.89.

In other Omnicell news, Director Joanne B. Bauer sold 3,798 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $81.72, for a total value of $310,372.56. Following the completion of the transaction, the director now owns 20,314 shares of the company’s stock, valued at $1,660,060.08. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Scott Peter Seidelmann sold 8,500 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $81.68, for a total transaction of $694,280.00. Following the completion of the transaction, the executive vice president now directly owns 28,929 shares of the company’s stock, valued at approximately $2,362,920.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 199,464 shares of company stock valued at $15,226,091. Corporate insiders own 2.77% of the company’s stock.

NASDAQ OMCL opened at $81.75 on Thursday. The firm has a market capitalization of $3.37 billion, a price-to-earnings ratio of 53.43, a P/E/G ratio of 2.65 and a beta of 1.20. Omnicell, Inc. has a 12-month low of $45.15 and a 12-month high of $86.87. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.96 and a quick ratio of 1.47.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, April 25th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.38. The business had revenue of $202.50 million during the quarter, compared to analysts’ expectations of $199.72 million. Omnicell had a net margin of 4.74% and a return on equity of 11.10%. The business’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter last year, the company posted $0.29 earnings per share. As a group, equities analysts anticipate that Omnicell, Inc. will post 2.06 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://theolympiareport.com/2019/05/23/new-york-state-teachers-retirement-system-acquires-5931-shares-of-omnicell-inc-omcl.html.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

Further Reading: How can you know how many shares are floating?

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.